Literature DB >> 16898869

Effect of dietary apigenin on colonic ornithine decarboxylase activity, aberrant crypt foci formation, and tumorigenesis in different experimental models.

Angela Au1, Boyong Li, Weiqun Wang, Hemant Roy, Ken Koehler, Diane Birt.   

Abstract

The efficacy of dietary apigenin, a dietary flavonoid, in colon cancer prevention was investigated by evaluating the inhibition of the ornithine decarboxylase (ODC) activity and the formation of aberrant crypt foci (ACF) and by studying the ability of apigenin to block colon carcinogenesis in two mouse models. First, the activity of ODC was measured in colon cancer cells (Caco-2) and in the colon epithelium of CF-1 mice. Apigenin at 10 and 30 muM significantly inhibited the ODC activity of Caco-2 cells by 26% and 57%, respectively. Colonic ODC activity in CF-1 mice was reduced with 0.1% dietary apigenin by 42% compared with the control, but this difference was not statistically significant. Second, ACF formation was evaluated in azoxymethane (AOM)-induced CF-1 mice. Female CF-1 mice at 6 wk of age were i.p. injected with 5 mg/kg body weight (BW) AOM once to induce ACF. ACF formation in CF-1 mice was reduced by 50% (P < 0.05) with 0.1% dietary apigenin fed for 6 wk when compared with the control. Dietary apigenin inhibited ACF only in the distal region of the CF-1 mouse colon. Finally, tumorigenesis studies were conducted using two different mouse models: AOM-induced CF-1 mice and Min mice with mutant adenomatous polyposis coli (APC) gene. Female CF-1 mice at 6 wk of age were i.p. injected with 10 mg/kg BW AOM weekly for 6 (AOM Study I) or 4 (AOM Study II) wk to induce tumors. CF-1 mice were fed diets containing 0.025% or 0.1% apigenin for 23-25 wk. Female Min mice were fed diets for 10 wk beginning at 5 wk of age. In two AOM-treated mouse colon tumor studies 0.025% and 0.1% dietary apigenin modestly reduced tumors in the group fed 0.025% apigenin (25% incidence in comparison with 65% in the controls) in a non-dose response manner. Apigenin failed to inhibit adenoma formation in the Min mouse study. These results suggest that dietary apigenin showed promise in cancer prevention by reducing the ODC activity and ACF formation, however, clear evidence of cancer prevention was not obtained in mouse tumor studies. Further investigation of the potential chemopreventive effect of apigenin in carcinogenesis is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898869     DOI: 10.1207/s15327914nc5402_11

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  10 in total

1.  Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.

Authors:  Huanjie Shao; Kai Jing; Esraa Mahmoud; Haihong Huang; Xianjun Fang; Chunrong Yu
Journal:  Mol Cancer Ther       Date:  2013-10-14       Impact factor: 6.261

2.  Apigenin suppresses the growth of colorectal cancer xenografts via phosphorylation and up-regulated FADD expression.

Authors:  Qi Rui Wang; Xue Qing Yao; Ge Wen; Qin Fan; Ying-Jia Li; Xiu Qiong Fu; Chang Ke Li; Xue Gang Sun
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

Review 3.  Role of pomegranate and citrus fruit juices in colon cancer prevention.

Authors:  Saravana Kumar Jaganathan; Muthu Vignesh Vellayappan; Gayathri Narasimhan; Eko Supriyanto
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53.

Authors:  Yi Zhong; Chutwadee Krisanapun; Seong-Ho Lee; Thararat Nualsanit; Carl Sams; Penchom Peungvicha; Seung Joon Baek
Journal:  Eur J Cancer       Date:  2010-08-13       Impact factor: 9.162

Review 5.  Apigenin: a promising molecule for cancer prevention.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Pharm Res       Date:  2010-03-20       Impact factor: 4.200

6.  Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats.

Authors:  Tety Leonardi; Jairam Vanamala; Stella S Taddeo; Laurie A Davidson; Mary E Murphy; Bhimanagouda S Patil; Naisyin Wang; Raymond J Carroll; Robert S Chapkin; Joanne R Lupton; Nancy D Turner
Journal:  Exp Biol Med (Maywood)       Date:  2010-06

Review 7.  Evidence for Anticancer Effects of Chinese Medicine Monomers on Colorectal Cancer.

Authors:  Tian-Hao Guo; Yuan-Yuan Li; Sheng-Wei Hong; Qian-Yu Cao; Heng Chen; Yuan Xu; Guo-Liang Dai; Gang Shao
Journal:  Chin J Integr Med       Date:  2022-04-13       Impact factor: 2.626

8.  Plant flavone apigenin: An emerging anticancer agent.

Authors:  Eswar Shankar; Aditi Goel; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

9.  Dietary flavonoids and colorectal adenoma recurrence in the Polyp Prevention Trial.

Authors:  Gerd Bobe; Leah B Sansbury; Paul S Albert; Amanda J Cross; Lisa Kahle; Jason Ashby; Martha L Slattery; Bette Caan; Electra Paskett; Frank Iber; James Walter Kikendall; Peter Lance; Cassandra Daston; James R Marshall; Arthur Schatzkin; Elaine Lanza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

Review 10.  Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment.

Authors:  Michelle Hanus; Daniela Parada-Venegas; Glauben Landskron; Ana Maria Wielandt; Claudia Hurtado; Karin Alvarez; Marcela A Hermoso; Francisco López-Köstner; Marjorie De la Fuente
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.